Skip to main content Help with accessibility Skip to main navigation


This section contains a list of the policy recommendations of the Pan Mersey Area Prescribing Committee.

Reviews of the new medicines have been conducted by our pharmacists using a number of resources including National Institute for Health and Clinical Excellence (NICE) which is a Special health Authority (SHA) set up in 1999. It is used to give advice to the NHS on best clinical practice including the clinical and cost effectiveness of drugs and other treatments.

Definitions and criteria for the categorisation of medicines

Legacy Merseyside
New Cheshire and Merseyside

Transition of Commissioning Policies

On 1st July 2022 NHS Cheshire and Merseyside Integrated Care Board (ICB) became the new statutory body responsible for ensuring health care services are available to meet the reasonable needs of the people of Cheshire & Merseyside.

Until such time as a single suite of commissioning policies can be developed and adopted, NHS Cheshire and Merseyside will continue to adopt and operate the CCG policies it has inherited at Place/borough level, which means that there will be no immediate change in commissioning policy for local people resident in those Places/boroughs from what was in place prior to 1st July 2022.

NHS Cheshire and Merseyside Commissioning Policies



Date Added: 24 - Jun - 2021

The Pan Mersey Area Prescribing Committee recommends Botulinum Toxin Type A injection by specialists for the treatment of achalasia, non-specific gastric motility disorder and functional or post-operative gastroparesis in adults.

Date Added: 23 - Oct - 2020

The Pan Mersey Area Prescribing Committee recommends prescribing a maximum of TWO COURSES of botulinum toxin type A injection in the treatment of chronic anal fissure which has not healed despite a minimum course of at least 8 weeks of topical management.

Date Added: 29 - Jul - 2021

The Pan Mersey Area Prescribing Committee recommends the prescribing of BUDESONIDE orodispersible tablets (Jorveza®▼), by specialists only, as a treatment option for inducing remission eosinophilic oesophagitis in adults (older than 18 years of age) in accordance with NICE TA708.